{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["1(9)"],"submitter":["Morgan BP"],"pubmed_abstract":["We report the design, synthesis, and optimization of the first, selective activators of cardiac myosin. Starting with a poorly soluble, nitro-aromatic hit compound (1), potent, selective, and soluble myosin activators were designed culminating in the discovery of omecamtiv mecarbil (24). Compound 24 is currently in clinical trials for the treatment of systolic heart failure."],"journal":["ACS medicinal chemistry letters"],"pagination":["472-7"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4007828"],"repository":["biostudies-literature"],"pubmed_title":["Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin."],"pmcid":["PMC4007828"],"pubmed_authors":["Morgan BP","Morgans DJ","Jiang H","Elias KA","Lee K","Anderson R","Muci A","Garard M","Djordjevic N","Kawas R","Sueoka S","Wang W","Wang Z","Rodriguez HM","Kraynack E","Valdez SC","Tomasi A","Xu D","Suehiro I","Godinez G","Tochimoto T","Qian X","Malik FI","Lu PP","Smith WW","Sylvester S","Collibee S","Hartman J"],"additional_accession":[]},"is_claimable":false,"name":"Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.","description":"We report the design, synthesis, and optimization of the first, selective activators of cardiac myosin. Starting with a poorly soluble, nitro-aromatic hit compound (1), potent, selective, and soluble myosin activators were designed culminating in the discovery of omecamtiv mecarbil (24). Compound 24 is currently in clinical trials for the treatment of systolic heart failure.","dates":{"release":"2010-01-01T00:00:00Z","publication":"2010 Dec","modification":"2025-04-04T22:38:42.086Z","creation":"2019-03-27T01:27:30Z"},"accession":"S-EPMC4007828","cross_references":{"pubmed":["24900233"],"doi":["10.1021/ml100138q"]}}